Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions [PDF]
Dermatology and TherapyIntroduction Spesolimab, a selective, humanised monoclonal antibody targeting the interleukin-36 receptor, is approved for the treatment of generalised pustular psoriasis (GPP).
Thomas Haeufel +2 more
exaly +3 more sources
Case report: Successful treatment with spesolimab of acrodermatitis continua of Hallopeau in an older patient without IL36RN mutations [PDF]
Frontiers in ImmunologyBackgroundAcrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular psoriasis variant refractory to many conventional treatments. The eruption typically occurs after local trauma or infection; other etiologies include neural, inflammatory ...
Jianfeng Zheng +2 more
exaly +4 more sources
Case Report: Spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy [PDF]
Frontiers in ImmunologyPyoderma gangrenosum (PG) is a classic neutrophilic dermatosis often associated with inflammatory conditions, frequently leading to misdiagnosis and delayed treatment. Drug-induced and postoperative are two potential triggers of PG.
Liyang Gu, Fang Du, Gu Liyang
exaly +4 more sources
Dermatology and Therapy, 2023 Introduction We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). Methods This phase IIb trial comprised a loading dose period to week (W) 4, then maintenance dosing to W52 ...
A D Burden, , Alexander A Navarini
exaly +2 more sources
Dermatology and Therapy, 2023 Introduction Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening skin disease. The global Effisayil 1 study investigated the efficacy and safety of spesolimab, a humanized monoclonal antibody targeting the IL-36 receptor, in ...
, Min Zheng, Yangfeng Ding
exaly +2 more sources
Combination therapy with spesolimab and apremilast for refractory generalized pustular psoriasis: a case report [PDF]
Frontiers in MedicineGeneralized pustular psoriasis (GPP) is a rare, life-threatening neutrophilic dermatosis characterized by recurrent episodes of widespread sterile pustules, systemic inflammation, and potential multi-organ failure.
Yuwei Li +4 more
doaj +2 more sources
Spesolimab Treatment in GPP: Impact of IL-36RN Mutations and Concomitant Plaque Psoriasis [PDF]
Clinical, Cosmetic and Investigational DermatologyWei Li,1– 3,* Jingyao Liang,2,* Yuwu Luo,2 Shuting Chen,2 Manqi Xia,2 Hui Ye,2 Bin Yang,1,3 Quan Luo2 1Department of Dermatology, First Affiliated Hospital of Jinan University, Guangzhou, 510630, People’s Republic of China; 2Department of
Li W +7 more
doaj +2 more sources
The efficacy and safety of spesolimab in patients with generalized pustular psoriasis flares: a systematic review and meta-analysis [PDF]
Frontiers in MedicineBackgroundGeneralized pustular psoriasis (GPP) is a rare, auto-inflammatory skin disease characterized by unpredictable flares, often requiring hospitalization, and current therapies lack robust evidence.ObjectivesTo systematically evaluate the efficacy ...
Dhaii Alzahrani +23 more
doaj +2 more sources
IL-36 Receptor Antagonist Spesolimab for Generalized Pustular Psoriasis Combined with Palmoplantar Pustulosis: A Case Report [PDF]
Clinical, Cosmetic and Investigational DermatologyHongyan Tan,1,* Yu Zhang,2,* Bin Zhang,3 Juan Wang,3 Zhong Zhang,3 Jizhen Zhong,3 Xiao Qiu,3 Xiangyu Hu,3 Ling Tang4 1Department of Dermatology, Shantou Hospital of Traditional Chinese Medicine, Shantou, 515031, People’s Republic of China;
Tan H +8 more
doaj +1 more source
Frontiers in ImmunologyGeneralized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening inflammatory disease, characterized by the rapid and widespread eruption of small, sterile pustules with surrounding skin erythema.
Eran C Gwillim, Anna Nichols
exaly +3 more sources